Who is the CEO of Otonomy, Inc.?

Mr. David M. Maggio is a business executive who currently serves as the CEO of Otonomy, Inc..

What is the Revenue Growth of Otonomy, Inc.?

Revenue growth data for Otonomy, Inc. is currently unavailable.

What is Otonomy, Inc. operating Margin?

Otonomy, Inc. operating margin is -39700.00% which shows how much profit OTIC earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Otonomy, Inc. operate?

Otonomy, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Otonomy, Inc. revenue growth?

Revenue growth data for Otonomy, Inc. is currently unavailable.

Otonomy, Inc.

OTIC•NASDAQ

HealthcareBiotechnology

$0.009

$-0.11(-92.64%)

Otonomy, Inc. (OTIC) Stock Overview

Explore Otonomy, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for OTICStats details for OTIC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for OTICAnalyst Recommendations details for OTIC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CEO

Mr. David M. Maggio

Employees

Headquarters

4796 Executive Drive, San Diego, CA

Founded

2014